FDA Revisits Rules on Drug and Device Communication: Will the Agency Relax Existing Industry-Opposed Restrictions?

The Food and Drug Administration issued draft guidances in January that tackled health care economic information and product labeling. Do these publications indicate a potential shift in on- and off-label policies for drugs and devices?